EMA Authorised: Optruma (raloxifene hydrochloride) — Eli Lilly Nederland B.V.

View source ↗

Summary

The EMA authorised Optruma (raloxifene hydrochloride) from Eli Lilly Nederland B.V. for osteoporosis in postmenopausal women.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Optruma (raloxifene hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis, Postmenopausal. MAH: Eli Lilly Nederland B.V.. Decision date: 27/01/2026